GLP-1

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock

2 December 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

INDIANAPOLIS — November 25, 2025 — Eli Lilly and Company (NYSE: LLY) continued its remarkable run on Tuesday, as the first-ever $1 trillion pharmaceutical company saw its stock climb again on the back of fresh analyst upgrades, intensifying obesity-drug momentum

25 November 2025

Company Analysis · Financial Updates · Investment News · NYSE:LLY · Pharmaceuticals · Stock Market

Hims & Hers Health (HIMS) Stock Today, November 23, 2025: Price, Buyback and GLP‑1 Risks

Hims & Hers Health (NYSE: HIMS) heads into the new week as one of the market’s most closely watched telehealth and weight‑loss plays — but also one of its most volatile. After Friday’s session (21 November 2025), HIMS closed at

23 November 2025

Financial Analysis · GLP-1 Drugs · Healthcare Stocks · Investing · Stock Market

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly’s stock is entering the new week as one of the most closely watched names on Wall Street. As of this weekend (Sunday, November 23, 2025), LLY is trading near $1,060 per share, valuing the company at roughly $1

23 November 2025

Financial News · Investment Strategies · Market Analysis · Pharmaceutical Industry · Stock Market

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO)

21 November 2025

Financial Analysis · Healthcare Industry · Investment News · NYSE:NVO · Pharmaceuticals · Stock Market

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

HIMS Stock Today (November 18, 2025): Buyback, GLP‑1 Price War and What It Means for Hims & Hers Investors

On Tuesday, November 18, 2025, Hims & Hers Health (NYSE: HIMS) is trading in the shadow of a sharp sell‑off, a fresh $250 million share repurchase authorization, and escalating price competition in the weight‑loss drug market. Together, these forces are

18 November 2025

Buyback · GLP‑1 · Health Tech · Investor News · NYSE:HIMS · Stocks

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and

17 November 2025

Drug Pricing · GLP-1 Medications · Healthcare News · Novo Nordisk · NYSE:LLY · NYSE:NVO · Pharmaceutical Industry

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss

17 November 2025

Business News · Drug Pricing · Healthcare · Pharma Industry · Stock Market

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO (NYSE) At a glance: price action and catalysts Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven

6 November 2025

Healthcare Policy · Investment News · Novo Nordisk · NYSE:NVO · Pharma Industry · Stock Market

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the day stockanalysis.com. This modest dip came amid a broader mixed market and ahead of the

4 November 2025

Company News · Financial Analysis · Healthcare · Investing · NYSE:HIMS · Stock Market

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by

3 November 2025

Expert Opinions · Healthcare Innovation · NYSE:HIMS · Stock Market · Weight Loss · Wellness Trends

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

LLY Stock Snapshot and Recent Moves Eli Lilly’s stock (NYSE: LLY) has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53 investing.com. After hitting highs in the

30 October 2025

AI Trends · Earnings Reports · Investment Strategies · NYSE:LLY · Pharmaceuticals · Stock Market